Immunohistochemistry of pulmonary biomarkers a perspective from members of the pulmonary pathology society Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Enzyme Activators
  • Protein Phosphatase 2
  • Proto-Oncogene Proteins p21(ras)

abstract

  • The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK and programmed death ligand-1 (PD-L1) (ROS1, EGFR in Europe) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes.

publication date

  • March 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.5858/arpa.2017-0106-SA

PubMed ID

  • 28686497

Additional Document Info

start page

  • 408

end page

  • 419

volume

  • 142

number

  • 3